Two-stage total hip arthroplasty: how often does it control methicillin-resistant infection?

Clin Orthop Relat Res. 2011 Apr;469(4):1009-15. doi: 10.1007/s11999-010-1725-6.

Abstract

Background: Methicillin-resistant hip infections are increasingly common. Reports of the surgical management of these patients using two-stage THA show variable control of infection, but all reports used static spacers.

Questions/purposes: We therefore determined (1) the rate of successful control of infection and (2) function in patients with methicillin-resistant infection treated with a two-stage THA using an articulated cement spacer during the first stage.

Methods: We retrospectively reviewed 50 patients who had a two-stage revision THA for methicillin-resistant Staphylococcus aureus or methicillin-resistant Staphylococcus epidermidis infection. Twelve patients died, leaving 38 for review. All eligible patients completed quality-of-life outcome questionnaires (WOMAC, SF-12, Oxford-12, UCLA activity score, hip and knee satisfaction score). Minimum followup was 24 months after the second stage (mean, 58 months; range, 24-123 months).

Results: Of the 38 patients, eight (21%) had recurrence of their infection requiring further revision surgery. Of the remaining 27 patients, the mean WOMAC was 62, mean Oxford-12 60, mean UCLA activity score 4.3, and mean hip and knee satisfaction score 66.

Conclusions: We found a treatment failure rate of 21% for patients with methicillin-resistant S. aureus or methicillin-resistant S. epidermidis infection. This is a higher rate than reported for two-stage THA for studies including patients infected with both nonresistant and resistant organisms. The functional scores for patients were also lower than those reported in the literature.

Level of evidence: Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Arthroplasty, Replacement, Hip / adverse effects*
  • Arthroplasty, Replacement, Hip / instrumentation
  • Bone Cements / therapeutic use
  • British Columbia
  • Chi-Square Distribution
  • Female
  • Hip Joint / microbiology
  • Hip Joint / physiopathology
  • Hip Joint / surgery*
  • Hip Prosthesis / adverse effects*
  • Humans
  • Infection Control / methods*
  • Logistic Models
  • Male
  • Methicillin-Resistant Staphylococcus aureus / pathogenicity*
  • Middle Aged
  • Patient Satisfaction
  • Prosthesis Design
  • Prosthesis-Related Infections / microbiology
  • Prosthesis-Related Infections / surgery*
  • Quality of Life
  • Range of Motion, Articular
  • Recovery of Function
  • Recurrence
  • Reoperation
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Staphylococcus epidermidis / pathogenicity*
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome

Substances

  • Bone Cements